JOHNSON & JOHNSON |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.9 EUR | -0.77% |
|
-1.53% | -5.84% |
| 07-02 | J&J: promising results in multiple myeloma | CF |
| 07-02 | Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| JOHNSON & JOHNSON | Other Pharmaceuticals | -0.77% | -1.53% | -5.84% | - | - | 351B | - | - | - |
Technical Rankings Surperformance
- Stock Market
- Equities
- JNJ Stock
- JNJ0 Stock
- Charts Johnson & Johnson
- Comparison Chart
